USD
GBP 
CNY 
EUR 
INR 
JPY 
MYR 
ZAR 
KRW 
THB 
Growth Opportunities in Radiopharmaceuticals
Emerging Interest from Big Pharma Players Is Pushing Industry Innovation Momentum
07-Oct-2025
Global
Technology Research
DB47-01-00-00-00
HC_2025_33930
The report covers the clinical trial assessment for radiodiagnostics, including PET, SPECT, and radiopharmaceuticals, comprising Alpha therapy, Beta therapy, Auger Therapy, and Theranostics. The report covers the key players in each space and their contributions to the radiopharmaceuticals landscape.
The report sheds light on technology innovations to make better radiopharmaceuticals. The radiopharmaceuticals industry is at the cusp of a high-confidence phase, with investors, CDMOs, and big pharmaceutical firms engaging in fundraising rounds, licensing agreements, acquisitions, and strategic collaborations. This research provides insights into partnerships, collaborations, acquisitions/mergers, and private funding activities that contribute to the growth of radiopharmaceuticals.
Key questions this report answers:
What are the key drivers and challenges for the development of radiopharmaceuticals?
What is the pace of clinical development in each segment?
Who are the leading industry participants developing innovative radiopharmaceuticals?
What does the funding and partnership landscape look like for radiopharmaceuticals?
What are the growth opportunities in radiopharmaceuticals?
Why Is It Increasingly Difficult to Grow?
The Strategic Imperative 8
The Impact of the Top 3 Strategic Imperatives on the Industry
Growth Opportunities Fuel the Growth Pipeline Engine
Research Methodology
Scope of Analysis
Segmentation
Growth Drivers
Growth Restraints
Introduction: Radiopharmaceuticals Gaining Traction
Radiodiagnostics
PET Analysis for Oncology
PET Imaging Radiopharmaceuticals
SPECT Analysis for Radio Diagnostics
Key Innovators—Radiodiagnostics
Radiotherapeutics
Comparative Analysis of Radiotherapies
Overview of the Radiotherapeutics Pipeline
Key Trends in Radiopharmaceuticals
Radiopharmaceuticals—Innovator Spotlight
Technological Innovation in Radiopharmaceuticals
Targeting Strategies and Radiochemistry Advances—Innovations
Novel Radioisotopes—Innovations
Drug Delivery—Innovations
Private Funding for Radiotherapeutics
Overview of the Acquisition Landscape for Radiopharmaceuticals
Partnership Landscape in Radiopharmaceuticals
Key Insights
Global M&A; Partnerships Landscape
Radiopharma Companies on Global Map
Insights from Radiopharmaceuticals Experts
Growth Opportunity 1: Focus on Alpha Therapies
Growth Opportunity 2: Focus on Radiotherapeutics
Growth Opportunity 3: Focus on Novel Targets
PET Imaging Radiopharmaceuticals
Clinical Pipeline Analysis of Key Industry Players—Radiotherapeutics
Technology Readiness Levels TRL: Explanation
Benefits and Impacts of Growth Opportunities
Next Steps
Legal Disclaimer
Speak directly with our analytics experts for tailored recommendations.
Recent related Pharmaceuticals research
31 Jul 2026 | Global | Market Research
Growth Opportunities in Small-Molecule Contract Development and Manufacturing Organizations, Global, 2026–2031
The global small‑molecule CDMO industry is undergoing a structural transformation driven by increasing molecular complexity, patent expiries, cost pressures, and the strategic need to secure resilient pharmaceutical supply chains. Demand is shifting beyond high‑volume commodity generics toward s...
30 Jul 2026 | Global | Frost Radar
Frost Radar™: Life Sciences Regulatory Information Management Platforms, 2026
The regulatory technology market in life sciences has, over the last five years, quietly transformed from a back-office category dominated by document repositories and submission publishing tools to one of the most consequential software segments serving the pharmaceutical, biotech, and medical devi...
17 Jul 2026 | Global | Technology Research
Innovations and Growth Opportunities in AI-Driven Drug Discovery, Precision Diagnostics, Advanced Biologics, and Next-generation Vaccines
This edition of the Life Science, Health & Wellness Technology Opportunity Engine (TOE) provides a comprehensive overview of breakthrough innovations reshaping drug discovery, diagnostics, and therapeutic delivery across oncology, infectious diseases, rare and autoimmune disorders, metabolic and age...
13 Jul 2026 | Global | Technology Research
RNA Therapies in Rare Diseases
Rare diseases pose a global burden to healthcare despite making up a very small fraction of the global disease landscape. Most treatment options for rare diseases focus on maintaining the disease symptoms, rather than a disease-modifying approach. To address this unmet need, RNA therapies are emergi...
08 Jul 2026 | Global | Technology Research
Precision Obesity Management: AI-Guided Metabolic Modulation
The report explores the transformation of obesity care from generalized BMI-based treatment to AI-enabled precision metabolic management. The study highlights how obesity is increasingly recognized as a heterogeneous, multi-pathway disease influenced by genetic, neurobehavioral, metabolic, and envir...
Purchase includes:
- Report download
- Growth Dialog™ with our experts
Growth Dialog™
A tailored session with you where we identify the:- Strategic Imperatives
- Growth Opportunities
- Best Practices
- Companies to Action
Impacting your company's future growth potential.
The report sheds light on technology innovations to make better radiopharmaceuticals. The radiopharmaceuticals industry is at the cusp of a high-confidence phase, with investors, CDMOs, and big pharmaceutical firms engaging in fundraising rounds, licensing agreements, acquisitions, and strategic collaborations. This research provides insights into partnerships, collaborations, acquisitions/mergers, and private funding activities that contribute to the growth of radiopharmaceuticals.
Key questions this report answers: What are the key drivers and challenges for the development of radiopharmaceuticals? What is the pace of clinical development in each segment? Who are the leading industry participants developing innovative radiopharmaceuticals? What does the funding and partnership landscape look like for radiopharmaceuticals? What are the growth opportunities in radiopharmaceuticals?
| Deliverable Type | Technology Research |
|---|---|
| Industries | Healthcare |
| No Index | No |
| Is Prebook | No |
| Keyword 1 | radiopharmaceuticals market |
| Keyword 2 | molecular imaging |
| Keyword 3 | targeted radio-therapies |
| Podcast | No |
| Predecessor | None |
| WIP Number | DB47-01-00-00-00 |